Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

NCT06503848 · clinicaltrials.gov ↗

RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: Sumatriptan

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Collaborators

[object Object]